我国海洋抗肿瘤药物的产业化出路

doi:10.13523/j.cb.20141218

中国生物工程杂志

2014, Vol. 34

Issue (12): 129-136 DOI: 10.13523/j.cb.20141218

生物产业

我国海洋抗肿瘤药物的产业化出路

林逸君

国家海洋局第三海洋研究所厦门 361005

Industrialization Strategy Research on Domestic Marine Anticancer Drugs

LIN Yi-Jun

Third Institute of Oceanography, State Oceanic Administration, Xiamen 361005, China

全文: PDF(573 KB) HTML

摘要：

海洋富含结构新颖的抗肿瘤活性物质,已成为全世界普遍关注的研究热点。国际已上市的海洋抗肿瘤药物有阿糖胞苷(Cytarabine)、曲贝替定(Ecteinascidin-743)、甲磺酸艾日布林(Eribulin mesylate)等,还有许多源自海洋生物的抗肿瘤候选药物正在进行临床前和临床研究。我国海洋抗肿瘤物质研究成果在国际上占有相当份额,但与产业化严重脱节。通过了解国内外海洋抗肿瘤药物的研究进展和产业方向,分析了我国海洋抗肿瘤药物产业化过程存在的药源开发不足、知识产权缺乏、资金投入不足、临床周期长等问题,提出了以市场需求,多学科相互交叉为基础,产学研合作模式为主体的自主知识产权药物研究体系,从关键技术、产品市场和产业政策等方面为加速我国海洋抗肿瘤药物的产业化提供有益思考。

关键词： 抗肿瘤; 产学研合作; 知识产权; 产业化

Abstract:

The marine has a largely source of novel compounds with potent anticancer activity and receives extensive attention from researchers. Recent studies in the field of marine anticancer drugs have revealed promising compounds with proven anticancer activity. Three examples are cytarabine, ecteinascidin-743 and eribulin mesylate, which represent the first three described marine anticancer drugs. In addition, there are a number of marine anticancer products in anticancer preclinical or clinical trials. The domestic studies of marine anticancer products play an important role in the international studies. But they are seriously out of line with the industrialization. The scientific advancements and development directions in marine anticancer drugs were examined. It analysis the industrialization problems in domestic marine anticancer drugs, such as insufficient development of marine anticancer resources, lack of intellectual property rights, insufficient capital investment, long period of clinical trials and so on. In order to solve the problems existing in industrial development and promote the healthy and orderly development of domestic marine anticancer drugs, highlights the viewpoint that the application rate of marine anticancer products can be increased greatly by the research system of autonomous intellectual property drug based on market demand and multidisciplinary technology in the "Industry-University-Institute" cooperation mode. The purpose is to put forward some useful suggestions for the industrialization of domestic marine anticancer drugs from the point of key technologies, market outlook and industrial policies.

Key words: Anticancer "Industry-University-Institute" cooperation Intellectual property Industrialization

收稿日期: 2014-07-28 出版日期: 2014-12-25

ZTFLH:

Q819

通讯作者: 林逸君 E-mail: linyijun0526@tio.org.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

林逸君. 我国海洋抗肿瘤药物的产业化出路[J]. 中国生物工程杂志, 2014, 34(12): 129-136.

LIN Yi-Jun. Industrialization Strategy Research on Domestic Marine Anticancer Drugs. China Biotechnology, 2014, 34(12): 129-136.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20141218 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I12/129

[1] Schumacher M, Kelkel M, Dicato M, et al. Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer. Biotechnology Advances, 2011, 29(5): 531-547.

[2] Dharmaraj S. Marine streptomyces as a novel source of bioactive substances. World Journal of Microbiology and Biotechnology, 2010, 26(12): 2123-2139.

[3] 管华诗, 王曙光. 中华海洋本草. 2009, 232-259. Guan S H, Wang S G. China marine materia medica.2009, 232-259.

[4] 邢桂兰, 田树红, 符健. 海洋细菌SSQ500的鉴定及其发酵产物抗肿瘤作用机制研究. 微生物学通报, 2013, 40(6): 1068-1073. Xing G L, Tian S H, Fu J. Identification of marine bacteria SSQ500 and the antitumor mechanism of fermentation products. Microbiology China,2013, 40(6): 1068-1073.

[5] Newman D J, Cragg G M. Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Marine Drugs, 2014, 12(1): 255-278.

[6] Huyck T K, Gradishar W, Manuguid F, et al. Eribulin mesylate. Nature Reviews Drug Discovery, 2011, 10(3): 173-174.

[7] Sarfaraj H M, Sheeba F, Saba A, et al. Marine natural products: a lead for anti-cancer. Indian Journal of Marine Sciences, 2012, 41: 27-39.

[8] Jiang C S, Muller W E G, Schroder H C, et al. Disulfide and multisulfide-containing metabolites from marine organisms. Chemical Reviews, 2011, 112(4): 2179-2207.

[9] Kawagishi F, Toma T, Inui T, et al. Total synthesis of ecteinascidin 743. Journal of the American Chemical Society, 2013, 135(37): 13684-13687.

[10] Pettit G R, Kamano Y, Herald C L, et al. Structure of bryostatin 4. An important antineoplastic constituent of geographically diverse Bugula neritina (Bryozoa). Journal of the American Chemical Society, 1984, 106(22): 6768-6771.

[11] Liu Y, Morgan J B, Coothankandaswamy V, et al. The Caulerpapigment caulerpin inhibits HIF-1 activation and mitochondrial respiration. Journal of Natural Products, 2009, 72(12): 2104-2109.

[12] Fuller R W, Cardellina J H, Kato Y, et al. A pentahalogenated monoterpene from the red alga Portieria hornemannii produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines. Journal of medicinal chemistry, 1992, 35: 3007-3011.

[13] Lin A S, Engel S, Smith B A, et al. Structure and biological evaluation of novel cytotoxic sterol glycosides from the marine red alga Peyssonnelia sp.. Bioorganic & Medicinal Chemistry, 2010, 18(23): 8264-8269.

[14] Colas S, Mahéo K, Denis F, et al. Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clinical Cancer Research, 2010, 12(19): 5879-5886.

[15] Cheng R B, Lin X Z, Wang Z K, et al. Establishment of a transgene expression system for the marine microalga Schizochytrium by 18S rDNA-targeted homologous recombination. World Journal of Microbiology and Biotechnology, 2011, 27(3): 737-741.

[16] Wyche T P, Hou Y, Braun D, et al. First natural analogs of the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp.. The Journal of Organic Chemistry, 2011, 76(16): 6542-6547.

[17] Lam K S, Lloyd G K, Neuteboom S T C, et al. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. Natural Products Chemistry for Drug Discovery, 2010, 355-373.

[18] Zheng L H, Wang Y J, Sheng J, et al. Antitumor peptides from marine organisms. Marine Drugs, 2011, 9(10): 1840-1859.

[19] Gerwick W H, Hamel E, White J D, et al. Integrating disciplines in the natural products sciences: the story of Curacin A. Planta Medica, 2012, 78(11):1-19.

[20] Lee J, Currano J N, Carroll P J, et al. Didemnins, tamandarins and related natural products. Natural Product Reports, 2012, 29(3): 404-424.

[21] Sivapathasekaran C, Das P, Mukherjee S, et al. Marine bacterium derived lipopeptides: characterization and cytotoxic activity against cancer cell lines. International Journal of Peptide Research and Therapeutics, 2010, 16(4): 215-222.

[22] Moushumi P A, Jayachandran S. Induction of apoptosis and cell cycle arrest by bis(2-ethylhexyl) phthalate produced by marine Bacillus pumilus MB 40. Chemico-biological Interactions, 2012, 195(2): 133-143.

[23] Maloney K N, Macmillan J B, Kauffman C A, et al. Lodopyridone, a structurally unprecedented alkaloid from a marine actinomycete. Organic Letters, 2009, 11(23): 5422-5424.

[24] 陈劲平, 林逸君, 敬科举, 等. 不同流加策略对内生真菌拟茎点霉生产去乙酰真菌环氧乙酯的影响. 厦门大学学报(自然科学版), 2010, 49(5): 676-681. Chen J P, Lin Y J, Jing K J, et al. Effect of different feeding modes on deacetylmycoepoxydiene production by an endophytic fungi Phomopsis sp. Journal of Xiamen University (Natural Science), 2010, 49(5):676681.

[25] 管华诗. 把握海洋药物研发的历史机遇. 中国海洋药物, 2013, 1: 14-15. Guan H S. Grasp the historical opportunity of marine drug. Chinese Journal of Marine Drugs, 2013, 1: 14-15.

[26] 张书军, 焦炳华. 世界海洋药物现状与发展趋势. 中国海洋药物, 2012, 2: 012. Zhang S J, Jiao B H. Current situation and development trend of marine drugs. Chinese Journal of Marine Drugs, 2012, 2: 012.

[27] 闫娟娟. 我国创新药物实现产业化的策略探讨. 中国医药管理杂志, 2011, 19(5): 397-399. Yan J J. Discussion on the strategy for industrialization of innovative medicine in our country. Journal of Traditional Chinese Medicine Management, 2011, 19(5): 397-399.

[28] Montaser R, Luesch H. Marine natural products: a new wave of drugs?. Future Medicinal Chemistry, 2011, 3(12): 1475-1489.

[29] 孙继鹏, 易瑞灶, 吴皓, 等. 海洋药物的研发现状及发展思路. 海洋开发与管理, 2013,3:7-13. Sun J P, Yi R Z, Wu H, et al. Research status and development ideas of marine drugs. Ocean Development and Management, 2013,3:7-13.

[1]	梁晋刚,张旭冬,毕研哲,王颢潜,张秀杰. 转基因抗虫玉米发展现状与展望^*[J]. 中国生物工程杂志, 2021, 41(6): 98-104.
[2]	邓蕊,曾佳利,卢雪梅. 基于Musca domestica cecropin的抗肿瘤小分子衍生肽筛选及构效关系解析^*[J]. 中国生物工程杂志, 2021, 41(11): 14-22.
[3]	杨威,宋方祥,王帅,张黎,王红霞,李焱. 药物输送系统中Janus纳米粒子的制备及应用 ^*[J]. 中国生物工程杂志, 2020, 40(7): 70-81.
[4]	童梅,程永庆,刘金毅,徐晨. 促进大肠杆菌周质空间小分子抗体表达的菌种构建方法^*[J]. 中国生物工程杂志, 2020, 40(5): 48-56.
[5]	卢钟腾,呼高伟. 新型细胞穿膜肽的鉴定方法与其在抗肿瘤治疗中的应用[J]. 中国生物工程杂志, 2019, 39(12): 50-55.
[6]	李思,翟逸舟,陆玉婷,王富军,赵健. 一种用于肿瘤药物治疗的新型人源性穿膜肽的优化及其应用 ^*[J]. 中国生物工程杂志, 2018, 38(7): 40-49.
[7]	李敏, 吴日伟. 抗肿瘤药物市场概述[J]. 中国生物工程杂志, 2017, 37(4): 125-133.
[8]	刘立平, 张纯, 殷爽, 王祺, 张耀, 余蓉, 刘永东, 苏志国. 白蛋白结合肽-多柔比星耦合物的设计、制备、表征及初步评价[J]. 中国生物工程杂志, 2017, 37(4): 68-75.
[9]	陈坤, 曹雪玮, 张琴, 赵健, 王富军. EGF类生长因子来源的新型靶向肽在抗肿瘤药物蛋白中的应用[J]. 中国生物工程杂志, 2017, 37(3): 1-9.
[10]	陈文杰, 汪建样, 殷明, 殷嫦嫦. 人脐带间充质干细胞抗肿瘤机制的研究进展[J]. 中国生物工程杂志, 2017, 37(3): 78-82.
[11]	沈平, 武玉花, 梁晋刚, 卢新, 章秋艳, 王颢潜, 刘鹏程. 转基因作物发展及应用概述[J]. 中国生物工程杂志, 2017, 37(1): 119-128.
[12]	沈平, 章秋艳, 林友华, 李文龙, 李昂, 宋贵文. 推进我国转基因玉米产业化的思考[J]. 中国生物工程杂志, 2016, 36(4): 24-29.
[13]	雷良欢, 黄同龙, 魏慧, 廖继燕, 吴雨婧, 周偲, 夏立秋, 张友明. 叶柄粘球菌STXZ77的分离鉴定及抗肿瘤活性[J]. 中国生物工程杂志, 2016, 36(11): 7-15.
[14]	周立军, 刘文娟, 祁永浩, 李妙. SOCS3通过JNK和STAT3信号通路调控AKT[J]. 中国生物工程杂志, 2015, 35(9): 50-56.
[15]	王世奇, 刘婧莹, 刘晨浪, 李纯, 胡晓凤, 夏立秋, 张友明. sTRAIL蛋白原核表达载体的构建、表达及抗肿瘤活性研究[J]. 中国生物工程杂志, 2015, 35(12): 1-7.

Viewed

Full text

Abstract

Cited

Shared

Discussed